North Carolina Headlines

Dementia Associated With Alzheimer’s Disease Pipeline Insight

Dementia associated with Alzheimer’s Disease Pipeline constitutes 80+ key companies continuously working towards developing 100+ Dementia associated with Alzheimer’s Disease treatment therapies, analyzes DelveInsight.

Dementia associated with Alzheimer’s Disease Overview:

Dementia is a general term that refers to a serious decline in cognitive function severe enough to interfere with daily life. The most common cause of dementia is Alzheimer’s disease (AD), which accounts for about two-thirds of cases in individuals aged 65 and older. Alzheimer’s is a progressive neurodegenerative disorder marked by the gradual deterioration of memory, thinking, language, and behavioral abilities. While Alzheimer’s itself is not a direct cause of death, it greatly increases the risk of other health complications that can lead to mortality.

Diagnosing Alzheimer’s-related dementia involves a comprehensive assessment that includes a detailed medical history, cognitive evaluations, physical and neurological examinations, and, when necessary, brain imaging. Physicians first rule out other possible causes of cognitive decline, such as nutrient deficiencies or thyroid dysfunction. Cognitive assessments help detect impairments in memory, language, and problem-solving, often revealing patterns specific to Alzheimer’s. Imaging techniques like MRI or CT scans may show brain shrinkage in characteristic areas, while advanced diagnostics such as PET scans or analysis of cerebrospinal fluid can identify biomarkers associated with the disease, providing stronger diagnostic support.

Currently, there is no cure for Alzheimer’s disease, and the damage to brain cells cannot be reversed. However, treatments are available to help manage symptoms and improve the quality of life for patients and caregivers. Cholinesterase inhibitors are among the commonly prescribed medications; they help improve communication between nerve cells and can temporarily reduce symptoms such as memory loss, confusion, and impaired judgment. The FDA has approved several drugs for symptom management, including donepezil (Aricept) for all stages of Alzheimer’s, and galantamine (Razadyne) and rivastigmine (Exelon) for mild to moderate stages of the disease.

Request for a detailed insights report on Dementia associated with Alzheimer’s Disease pipeline insights

“Dementia associated with Alzheimer’s Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Dementia associated with Alzheimer’s Disease Therapeutics Market.

Key Takeaways from the Dementia associated with Alzheimer’s Disease Pipeline Report

• DelveInsight’s Dementia associated with Alzheimer’s Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia associated with Alzheimer’s Disease treatment.

• In September 2025, Japan’s Ministry of Health, Labour, and Welfare approved KISUNLA (donanemab-azbt, 350 mg/20 mL) for intravenous infusion every four weeks. Developed by Eli Lilly, this treatment is designed for adults with early symptomatic Alzheimer’s disease, including mild dementia, who have confirmed amyloid pathology.

• In July 2025, the FDA approved Eli Lilly’s donanemab, an anti-amyloid antibody, making it the third drug intended to modify the progression of Alzheimer’s disease. This approval is expected to intensify competition between Eli Lilly’s donanemab and Biogen and Eisai’s ADUHELM (aducanumab) and LEQEMBI (lecanemab).

• Key Dementia associated with Alzheimer’s Disease companies such as BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others are evaluating new drugs for Dementia associated with Alzheimer’s Disease to improve the treatment landscape.

• Promising Dementia associated with Alzheimer’s Disease pipeline therapies in various stages of development include NE3107, KarXT, Simufilam, CT-1812, CM383, and others.

Dementia associated with Alzheimer’s Disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Dementia associated with Alzheimer’s Disease Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dementia associated with Alzheimer’s Disease treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Dementia associated with Alzheimer’s Disease market.

Download our free sample page report on Dementia associated with Alzheimer’s Disease pipeline insights

Dementia associated with Alzheimer’s Disease Emerging Drugs

• NE3107: BioVie

• KarXT: Karuna Therapeutics

• Simufilam: Cassava Sciences

• CT-1812: Cognition Therapeutics

• CM383: KeyMed Biosciences

Dementia associated with Alzheimer’s Disease Companies

More than 80 leading companies are actively engaged in developing treatments for Dementia Associated with Alzheimer’s Disease. Among these, BioVie, Karuna Therapeutics, and Cassava Sciences have advanced their drug candidates to the most progressed stage of development—Phase III clinical trials.

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Dementia associated with Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Dementia associated with Alzheimer’s Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Dementia associated with Alzheimer’s Disease Therapies and Key Companies: Dementia associated with Alzheimer’s Disease Clinical Trials and advancements

Dementia associated with Alzheimer’s Disease Pipeline Therapeutic Assessment

• Dementia associated with Alzheimer’s Disease Assessment by Product Type

• Dementia associated with Alzheimer’s Disease By Stage

• Dementia associated with Alzheimer’s Disease Assessment by Route of Administration

• Dementia associated with Alzheimer’s Disease Assessment by Molecule Type

Download Dementia associated with Alzheimer’s Disease Sample report to know in detail about the Dementia associated with Alzheimer’s Disease treatment market @ Dementia associated with Alzheimer’s Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Dementia associated with Alzheimer’s Disease Current Treatment Patterns

4. Dementia associated with Alzheimer’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Dementia associated with Alzheimer’s Disease Late-Stage Products (Phase-III)

7. Dementia associated with Alzheimer’s Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dementia associated with Alzheimer’s Disease Discontinued Products

13. Dementia associated with Alzheimer’s Disease Product Profiles

14. Dementia associated with Alzheimer’s Disease Key Companies

15. Dementia associated with Alzheimer’s Disease Key Products

16. Dormant and Discontinued Products

17. Dementia associated with Alzheimer’s Disease Unmet Needs

18. Dementia associated with Alzheimer’s Disease Future Perspectives

19. Dementia associated with Alzheimer’s Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Dementia associated with Alzheimer’s Disease Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/